Evidence map›Paper›PMID 36296225›Full record

ArticleMicroorganisms2022

Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia.

Vasilis Petrakis, Vasiliki Rapti, Karolina Akinosoglou, Constantinos Bonelis, Kalomoira Athanasiou, Vasiliki Dimakopoulou, Nikolaos K Syrigos, Nikolaos Spernovasilis, Grigoris Trypsianis, Markos Marangos and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Vasilis Petrakis2nd Department of Internal Medicine, Democritus University of Thrace, University General Hospital Alexandroupolis, 68100 Alexadroupolis, Greece.
Vasiliki Rapti3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527 Athens, Greece.
Karolina AkinosoglouDepartment of Internal Medicine and Infectious Diseases, Medical School, University of Patras, 26504 Patras, Greece.ORCID 0000-0002-4289-9494
Constantinos Bonelis2nd Department of Internal Medicine, Democritus University of Thrace, University General Hospital Alexandroupolis, 68100 Alexadroupolis, Greece.
Kalomoira Athanasiou3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527 Athens, Greece.
Vasiliki DimakopoulouDepartment of Internal Medicine, Medical School, University of Patras, 26504 Patras, Greece.
Nikolaos K Syrigos3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527 Athens, Greece.ORCID 0000-0001-8082-594X
Nikolaos SpernovasilisSchool of Medicine, University of Crete, 71500 Heraklion, Greece.ORCID 0000-0002-6981-8535
Grigoris TrypsianisDepartment of Medical Statistics, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0002-2544-1721
Markos MarangosDepartment of Internal Medicine and Infectious Diseases, Medical School, University of Patras, 26504 Patras, Greece.
Charalambos GogosDepartment of Internal Medicine, Medical School, University of Patras, 26504 Patras, Greece.
Dimitrios Papazoglou2nd Department of Internal Medicine, Democritus University of Thrace, University General Hospital Alexandroupolis, 68100 Alexadroupolis, Greece.
Periklis Panagopoulos2nd Department of Internal Medicine, Democritus University of Thrace, University General Hospital Alexandroupolis, 68100 Alexadroupolis, Greece.
Garyfallia Poulakou3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, 11527 Athens, Greece.
Democritus University of Thrace · GRUniversity of Patras · GRNational and Kapodistrian University of Athens · GRHarvard University · USUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as a standard of care. Nevertheless, controversial reports have been published. The aim of the present study is to evaluate the effectiveness of remdesivir in hospitalized patients with COVID-19 pneumonia at three Greek University Departments of Infectious Diseases with homogenous treatment protocols. From September 2020 to February 2021, we retrospectively analyzed adults hospitalized with confirmed SARS-CoV-2 infection and radiological findings of pneumonia, who received remdesivir once daily for five days. Exploratory end points were duration of hospitalization, time of intubation, and death. Overall, 551 patients were included in the study. The optimal cutoff point for the number of days needed after symptom initiation for drug administration associated with better clinical outcome was 7 days. Higher odds for discharge and lower for intubation were observed in patients with treatment initiation ≤7 days (

Indexed as

COVID-19dischargeintubationpandemicremdesivirretrospective studySARS-CoV-2

Identifiers

PMID36296225
PMCPMC9611983
OpenAlexW4303856971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.